lidorestat
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 13, 2002 (NCT00043797)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Aldose reductaseINHIBITOR
AKR1B1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)Cn1cc(Cc2nc3c(F)c(F)cc(F)c3s2)c2ccccc21- Mol. weight
- 376.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL363387 ↗
Also known as
- 3-((4,5,7-trifluorobenzothiazol-2-yl)methyl)indole-n-acetic acid
- idd-000676-01
- idd-000676-01
- idd-676
- idd-676
- lidorestat
- lidorestat
- lidorestat
- lidorestat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00043797 | Phase 2 | Aug 13, 2002 | The Institute for Diabetes Discovery, LLC |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| The Institute for Diabetes Discovery, LLC | Academic/Hospital | 1 | 1 | 1 | 2002 |
1 organizations
Page 1 / 1